Review



kcas bio analytical  (KCAS Bioanalytical and Biomarker Services)


Bioz Verified Symbol KCAS Bioanalytical and Biomarker Services is a verified supplier
Bioz Manufacturer Symbol KCAS Bioanalytical and Biomarker Services manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    KCAS Bioanalytical and Biomarker Services kcas bio analytical
    Kcas Bio Analytical, supplied by KCAS Bioanalytical and Biomarker Services, used in various techniques. Bioz Stars score: 99/100, based on 612 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibody+microarray/Large+Molecule+Bioanalysis/pm40684393-96-17-17
    Average 99 stars, based on 612 article reviews
    kcas bio analytical - by Bioz Stars, 2026-11
    99/100 stars

    Images

    Related Articles

    Biomarker Discovery:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Drug discovery:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    DNA Synthesis:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Imaging:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Clinical Proteomics:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Magnetic Resonance Imaging:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Diagnostic Assay:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Virus:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Neutralization:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Incubation:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Control:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;



    Similar Products

    94
    RayBiotech inc antibody microarrays
    Antibody Microarrays, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibody+microarray/Human+Immune+Response+Array+GS1/pm42565727-46-14-19
    Average 94 stars, based on 1 article reviews
    antibody microarrays - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    RayBiotech inc glass slide based antibody cytokine microarray
    Glass Slide Based Antibody Cytokine Microarray, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibody+microarray/Human+Cytokine+Array+GS4000/pm42271436-155-29-34
    Average 94 stars, based on 1 article reviews
    glass slide based antibody cytokine microarray - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    91
    Proteintech microarray chip
    Microarray Chip, supplied by Proteintech, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibody+microarray/FUT9+Antibody/pm41872462-70-27-23
    Average 91 stars, based on 1 article reviews
    microarray chip - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    86
    Kinexus Bioinformatics Corporation antibody microarray
    ( A ) Experimental workflow used for phosphoproteomic analysis of F508del-CFBE41o- cells treated with control peptide (CP) or PI3Kγ MP (25 μM, 30 minutes). A phospho-specific <t>microarray,</t> containing 875 phosphosite-specific and 451 pan-specific antibodies, was used. Thirty-six proteins showing phosphorylation changes exceeding ±60% compared with the control (expressed as percentage CFC, i.e., percentage fold-change compared with control) were selected for downstream analysis. ( B and C ) Panther Gene Ontology (GO) slim-term enrichment analysis of proteins with altered phosphorylation after PI3Kγ MP treatment. Significantly enriched GO terms (FDR < 0.05) were categorized under ( B ) biological processes and ( C ) cellular components. ( D ) Reactome pathway enrichment analysis of differentially phosphorylated proteins after PI3Kγ MP treatment. Lines represent the top 20 pathways; x axis shows the –log 10 (FDR). Color intensity reflects fold enrichment, and circle size indicates the number of proteins; color intensity (yellow to red) indicates increasing fold enrichment. The full phospho-array protein list served as background reference. ( E ) Proteins with CFC greater than 60% (green) or less than −60% (red). A CFC of 100% corresponds to a 2-fold increase in signal intensity after PI3Kγ MP treatment relative to CP.
    Antibody Microarray, supplied by Kinexus Bioinformatics Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibody+microarray/antibody+microarray/pmc13043088-153-35-46
    Average 86 stars, based on 1 article reviews
    antibody microarray - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    96
    SCIENION printing antibody microarrays
    ( A ) Experimental workflow used for phosphoproteomic analysis of F508del-CFBE41o- cells treated with control peptide (CP) or PI3Kγ MP (25 μM, 30 minutes). A phospho-specific <t>microarray,</t> containing 875 phosphosite-specific and 451 pan-specific antibodies, was used. Thirty-six proteins showing phosphorylation changes exceeding ±60% compared with the control (expressed as percentage CFC, i.e., percentage fold-change compared with control) were selected for downstream analysis. ( B and C ) Panther Gene Ontology (GO) slim-term enrichment analysis of proteins with altered phosphorylation after PI3Kγ MP treatment. Significantly enriched GO terms (FDR < 0.05) were categorized under ( B ) biological processes and ( C ) cellular components. ( D ) Reactome pathway enrichment analysis of differentially phosphorylated proteins after PI3Kγ MP treatment. Lines represent the top 20 pathways; x axis shows the –log 10 (FDR). Color intensity reflects fold enrichment, and circle size indicates the number of proteins; color intensity (yellow to red) indicates increasing fold enrichment. The full phospho-array protein list served as background reference. ( E ) Proteins with CFC greater than 60% (green) or less than −60% (red). A CFC of 100% corresponds to a 2-fold increase in signal intensity after PI3Kγ MP treatment relative to CP.
    Printing Antibody Microarrays, supplied by SCIENION, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibody+microarray/sciFLEXARRAYER+S3/pmc12980523-117-8-3
    Average 96 stars, based on 1 article reviews
    printing antibody microarrays - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    86
    Kinexus Bioinformatics Corporation kinexus antibody microarrays
    ( A ) Experimental workflow used for phosphoproteomic analysis of F508del-CFBE41o- cells treated with control peptide (CP) or PI3Kγ MP (25 μM, 30 minutes). A phospho-specific <t>microarray,</t> containing 875 phosphosite-specific and 451 pan-specific antibodies, was used. Thirty-six proteins showing phosphorylation changes exceeding ±60% compared with the control (expressed as percentage CFC, i.e., percentage fold-change compared with control) were selected for downstream analysis. ( B and C ) Panther Gene Ontology (GO) slim-term enrichment analysis of proteins with altered phosphorylation after PI3Kγ MP treatment. Significantly enriched GO terms (FDR < 0.05) were categorized under ( B ) biological processes and ( C ) cellular components. ( D ) Reactome pathway enrichment analysis of differentially phosphorylated proteins after PI3Kγ MP treatment. Lines represent the top 20 pathways; x axis shows the –log 10 (FDR). Color intensity reflects fold enrichment, and circle size indicates the number of proteins; color intensity (yellow to red) indicates increasing fold enrichment. The full phospho-array protein list served as background reference. ( E ) Proteins with CFC greater than 60% (green) or less than −60% (red). A CFC of 100% corresponds to a 2-fold increase in signal intensity after PI3Kγ MP treatment relative to CP.
    Kinexus Antibody Microarrays, supplied by Kinexus Bioinformatics Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibody+microarray/antibody+microarrays+phospho/10__1042_slash_cs20258127-88-7-10
    Average 86 stars, based on 1 article reviews
    kinexus antibody microarrays - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    86
    Kinexus Bioinformatics Corporation kinexus antibody microarray profiling
    ( A ) Experimental workflow used for phosphoproteomic analysis of F508del-CFBE41o- cells treated with control peptide (CP) or PI3Kγ MP (25 μM, 30 minutes). A phospho-specific <t>microarray,</t> containing 875 phosphosite-specific and 451 pan-specific antibodies, was used. Thirty-six proteins showing phosphorylation changes exceeding ±60% compared with the control (expressed as percentage CFC, i.e., percentage fold-change compared with control) were selected for downstream analysis. ( B and C ) Panther Gene Ontology (GO) slim-term enrichment analysis of proteins with altered phosphorylation after PI3Kγ MP treatment. Significantly enriched GO terms (FDR < 0.05) were categorized under ( B ) biological processes and ( C ) cellular components. ( D ) Reactome pathway enrichment analysis of differentially phosphorylated proteins after PI3Kγ MP treatment. Lines represent the top 20 pathways; x axis shows the –log 10 (FDR). Color intensity reflects fold enrichment, and circle size indicates the number of proteins; color intensity (yellow to red) indicates increasing fold enrichment. The full phospho-array protein list served as background reference. ( E ) Proteins with CFC greater than 60% (green) or less than −60% (red). A CFC of 100% corresponds to a 2-fold increase in signal intensity after PI3Kγ MP treatment relative to CP.
    Kinexus Antibody Microarray Profiling, supplied by Kinexus Bioinformatics Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibody+microarray/antibody+kinexus+microarray+profiling/10__1042_slash_cs20258127-60-1-1
    Average 86 stars, based on 1 article reviews
    kinexus antibody microarray profiling - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    86
    Charles River Laboratories anti ccr8 antibodies retrogenix cell microarray technology
    ( A ) Experimental workflow used for phosphoproteomic analysis of F508del-CFBE41o- cells treated with control peptide (CP) or PI3Kγ MP (25 μM, 30 minutes). A phospho-specific <t>microarray,</t> containing 875 phosphosite-specific and 451 pan-specific antibodies, was used. Thirty-six proteins showing phosphorylation changes exceeding ±60% compared with the control (expressed as percentage CFC, i.e., percentage fold-change compared with control) were selected for downstream analysis. ( B and C ) Panther Gene Ontology (GO) slim-term enrichment analysis of proteins with altered phosphorylation after PI3Kγ MP treatment. Significantly enriched GO terms (FDR < 0.05) were categorized under ( B ) biological processes and ( C ) cellular components. ( D ) Reactome pathway enrichment analysis of differentially phosphorylated proteins after PI3Kγ MP treatment. Lines represent the top 20 pathways; x axis shows the –log 10 (FDR). Color intensity reflects fold enrichment, and circle size indicates the number of proteins; color intensity (yellow to red) indicates increasing fold enrichment. The full phospho-array protein list served as background reference. ( E ) Proteins with CFC greater than 60% (green) or less than −60% (red). A CFC of 100% corresponds to a 2-fold increase in signal intensity after PI3Kγ MP treatment relative to CP.
    Anti Ccr8 Antibodies Retrogenix Cell Microarray Technology, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibody+microarray/cell+microarray+screen+technology/10__1158_slash_1535___7163__mct___25___0367-84-5-7
    Average 86 stars, based on 1 article reviews
    anti ccr8 antibodies retrogenix cell microarray technology - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    93
    Proteintech tissue microarrays
    A Schematic diagram of the ALYREF m 5 C methylation binding site mutation. B m 5 C-RIP and qRT-PCR assays detecting the influence of ALYREF on the m 5 C methylation level of LGR4 mRNA. C qPCR detection of LGR4 RNA expression in the influence of ALYREF. D Western blot analysis of LGR4 protein expression in ALYREF-overexpressing A2780/DDP and SKOV3/DDP cells, and in cells with mutated ALYREF binding sites. E Actinomycin D assay assessing the impact of ALYREF on LGR4 mRNA stability. F Representative images of IHC staining of LGR4 expression levels in tissue <t>microarrays.</t> G Correlation analysis between ALYREF and LGR4 protein expression levels. H Schematic representation of the subcutaneous tumor model in cisplatin-resistant ovarian cancer-bearing mice by Generic Diagramming Platform (GDP) . I Final diameter and weight of the subcutaneous tumors. Data are displayed as mean ± SD; *: p < 0.05. **: p < 0.01. ***: p < 0.001. ****: p < 0.0001.
    Tissue Microarrays, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibody+microarray/ALY+Antibody/pmc12827963-124-6-20
    Average 93 stars, based on 1 article reviews
    tissue microarrays - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Experimental workflow used for phosphoproteomic analysis of F508del-CFBE41o- cells treated with control peptide (CP) or PI3Kγ MP (25 μM, 30 minutes). A phospho-specific microarray, containing 875 phosphosite-specific and 451 pan-specific antibodies, was used. Thirty-six proteins showing phosphorylation changes exceeding ±60% compared with the control (expressed as percentage CFC, i.e., percentage fold-change compared with control) were selected for downstream analysis. ( B and C ) Panther Gene Ontology (GO) slim-term enrichment analysis of proteins with altered phosphorylation after PI3Kγ MP treatment. Significantly enriched GO terms (FDR < 0.05) were categorized under ( B ) biological processes and ( C ) cellular components. ( D ) Reactome pathway enrichment analysis of differentially phosphorylated proteins after PI3Kγ MP treatment. Lines represent the top 20 pathways; x axis shows the –log 10 (FDR). Color intensity reflects fold enrichment, and circle size indicates the number of proteins; color intensity (yellow to red) indicates increasing fold enrichment. The full phospho-array protein list served as background reference. ( E ) Proteins with CFC greater than 60% (green) or less than −60% (red). A CFC of 100% corresponds to a 2-fold increase in signal intensity after PI3Kγ MP treatment relative to CP.

    Journal: JCI Insight

    Article Title: Targeting PI3K γ anchoring enhances CFTR membrane localization and modulator efficacy via PKD1

    doi: 10.1172/jci.insight.198846

    Figure Lengend Snippet: ( A ) Experimental workflow used for phosphoproteomic analysis of F508del-CFBE41o- cells treated with control peptide (CP) or PI3Kγ MP (25 μM, 30 minutes). A phospho-specific microarray, containing 875 phosphosite-specific and 451 pan-specific antibodies, was used. Thirty-six proteins showing phosphorylation changes exceeding ±60% compared with the control (expressed as percentage CFC, i.e., percentage fold-change compared with control) were selected for downstream analysis. ( B and C ) Panther Gene Ontology (GO) slim-term enrichment analysis of proteins with altered phosphorylation after PI3Kγ MP treatment. Significantly enriched GO terms (FDR < 0.05) were categorized under ( B ) biological processes and ( C ) cellular components. ( D ) Reactome pathway enrichment analysis of differentially phosphorylated proteins after PI3Kγ MP treatment. Lines represent the top 20 pathways; x axis shows the –log 10 (FDR). Color intensity reflects fold enrichment, and circle size indicates the number of proteins; color intensity (yellow to red) indicates increasing fold enrichment. The full phospho-array protein list served as background reference. ( E ) Proteins with CFC greater than 60% (green) or less than −60% (red). A CFC of 100% corresponds to a 2-fold increase in signal intensity after PI3Kγ MP treatment relative to CP.

    Article Snippet: After treatment with 25 μM PI3Kγ MP or an equimolar amount of CP for 30 minutes, F508del-CFBE41o- cells were lysed as described above, and protein samples were frozen at –80°C before being subjected to an antibody microarray (KAM-1325 array) and data analysis, which was performed at Kinexus.

    Techniques: Control, Microarray, Phospho-proteomics

    A Schematic diagram of the ALYREF m 5 C methylation binding site mutation. B m 5 C-RIP and qRT-PCR assays detecting the influence of ALYREF on the m 5 C methylation level of LGR4 mRNA. C qPCR detection of LGR4 RNA expression in the influence of ALYREF. D Western blot analysis of LGR4 protein expression in ALYREF-overexpressing A2780/DDP and SKOV3/DDP cells, and in cells with mutated ALYREF binding sites. E Actinomycin D assay assessing the impact of ALYREF on LGR4 mRNA stability. F Representative images of IHC staining of LGR4 expression levels in tissue microarrays. G Correlation analysis between ALYREF and LGR4 protein expression levels. H Schematic representation of the subcutaneous tumor model in cisplatin-resistant ovarian cancer-bearing mice by Generic Diagramming Platform (GDP) . I Final diameter and weight of the subcutaneous tumors. Data are displayed as mean ± SD; *: p < 0.05. **: p < 0.01. ***: p < 0.001. ****: p < 0.0001.

    Journal: Cell Death & Disease

    Article Title: Multi-omics analysis reveals that ALYREF-mediated m 5 C modification promotes platinum resistance in ovarian cancer via the NSUN2/ALYREF/LGR4 axis

    doi: 10.1038/s41419-025-08310-8

    Figure Lengend Snippet: A Schematic diagram of the ALYREF m 5 C methylation binding site mutation. B m 5 C-RIP and qRT-PCR assays detecting the influence of ALYREF on the m 5 C methylation level of LGR4 mRNA. C qPCR detection of LGR4 RNA expression in the influence of ALYREF. D Western blot analysis of LGR4 protein expression in ALYREF-overexpressing A2780/DDP and SKOV3/DDP cells, and in cells with mutated ALYREF binding sites. E Actinomycin D assay assessing the impact of ALYREF on LGR4 mRNA stability. F Representative images of IHC staining of LGR4 expression levels in tissue microarrays. G Correlation analysis between ALYREF and LGR4 protein expression levels. H Schematic representation of the subcutaneous tumor model in cisplatin-resistant ovarian cancer-bearing mice by Generic Diagramming Platform (GDP) . I Final diameter and weight of the subcutaneous tumors. Data are displayed as mean ± SD; *: p < 0.05. **: p < 0.01. ***: p < 0.001. ****: p < 0.0001.

    Article Snippet: Following a rinse with PBS, the tissue microarrays were incubated at 4 °C for 16 h with anti-ALYREF antibody (16690-1-AP; Proteintech, China) and anti-LGR4 antibody (20150-1-AP; Proteintech, China), each at a 1:300 dilution.

    Techniques: Methylation, Binding Assay, Mutagenesis, Quantitative RT-PCR, RNA Expression, Western Blot, Expressing, Immunohistochemistry